Monitor for any shareholder dissent on executive compensation or director elections, though the board's unanimous recommendations and recent executive appointments suggest stability. The insider selling activity noted in the market snapshot may warrant further investigation into executive sentiment.
Price Chart
Executive Summary
Tango Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Class II directors, ratification of its auditor, and approval of executive compensation. This is a routine annual proxy filing, and recent executive changes suggest ongoing leadership transitions.
Key Facts
- Shareholders will vote on the re-election of directors Malte Peters, M.D., Kanishka Pothula, and Mace Rothenberg, M.D.
- The board recommends ratifying PricewaterhouseCoopers LLP as the independent auditor.
- The board recommends approving the compensation of named executive officers.
- Recent executive changes include the appointment of Matthew Gall as CFO and Jessica Newcomb as principal accounting officer.
- The filing is a standard annual proxy statement for the June 4, 2026, shareholder meeting.
Financial Impact
No direct financial impact from this filing. The recent executive appointments may influence future financial reporting and strategy.
Risk Factors
- Potential for shareholder activism if compensation packages are perceived as excessive.
- Leadership transition risk following recent executive appointments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-160320 |
| Document: 0001193125-26-160320-index-headers.html | 0001193125-26-160320 |
| Document: 0001193125-26-160320-index.html | 0001193125-26-160320 |
| Document: 0001193125-26-160320.txt | 0001193125-26-160320 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $25.58 $25.20 | ▲ +1.49% | ▲ +1.04% | $23.20 (+9.28%) |
Aug 11, 2026 7w ago | 8-K | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 11, 2026 7w ago | Press Release | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 9, 2026 7w ago | Institutional Cluster | $27.67 $25.29 | ▼ −8.60% | ▼ −8.55% | $23.20 (−16.14%) |
Aug 6, 2026 8w ago | 8-K | $27.07 $25.60 | ▼ −5.43% | ▼ −5.83% | $23.20 (−14.28%) |
Jun 11, 2026 16w ago | 144 | $30.94 $27.97 | ▼ −9.60% | ▼ −10.27% | $23.20 (−25.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 424B5 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 144 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access